Skip to main content

Oncology

Sep 22
Love0

Aranscia Announces Molecular Laboratory Integration Initiative with Northside Hospital to Advance Precision Oncology

By News

Aranscia Announces Molecular Laboratory Integration Initiative with Northside Hospital to Advance Precision Oncology

Initiative integrates Aranscia’s 2bPrecise and Spesana platforms with leading molecular laboratories to streamline genomic testing across Northside’s cancer care network

ATLANTA, GA — September 22, 2026 — Aranscia today announced a new initiative with Northside Hospital Cancer Institute designed to advance precision medicine and improve the integration of molecular diagnostic testing throughout its health system. Through the collaboration with Northside, Aranscia and its network of 12 leading molecular laboratories are creating a more connected molecular diagnostic ecosystem designed to make genomic testing easier to order, results easier to access, and clinically relevant information more actionable for physicians and care teams.

Historically, disparate laboratories have operated through different ordering processes, reporting formats, and technology platforms. This fragmentation can create challenges for clinicians and care teams seeking to efficiently order testing, track results, and incorporate molecular findings into treatment decisions.

Through this integration, Aranscia’s platform of software solutions, including 2bPrecise and Spesana, will enhance Northside Hospital Cancer Institute’s existing clinical, operational and analytical workflows with unified molecular diagnostic reports and discrete genomic data directly within Northside’s Oracle Health system. This functionality will help clinicians more efficiently incorporate diagnostic information into coordinated, patient-centered care. Northside clinicians will also benefit from the translation of complex genetic data into actionable insights that can guide treatment planning, help identify therapy opportunities, and support long-term patient care.

“This initiative represents an important step in our continued efforts to bring precision medicine into the everyday clinical workflow,” said Amy Boren, Director of Oncology Services at Northside Hospital. “By connecting our clinicians with a broader molecular laboratory ecosystem, we can help make genomic testing more accessible, more coordinated, and more actionable. Most importantly, this work is about ensuring that patients and their care teams can derive the greatest possible value from the increasingly important role of molecular diagnostics in cancer care.”

Beyond the immediate benefits, this integration also provides Northside with a foundation for continued innovation in precision oncology and genomic medicine. As the volume and complexity of molecular testing continues to grow, the ability to efficiently manage, organize, and utilize genomic information will become increasingly important to delivering high-quality care.

“Northside Hospital Cancer Institute has built a reputation for delivering exceptional cancer care to those directly within its communities,” said Carla Balch, Executive Director, Software & Products at Aranscia. “We are honored to support their continued leadership in precision medicine and their commitment to improving access and outcomes for all patients, directly within clinical EHR workflows.”

About Northside Hospital

Northside Hospital is Georgia’s leading healthcare system, serving patients at five acute-care hospitals in Atlanta, Canton, Cumming, Duluth and Lawrenceville and nearly 500 outpatient locations across the state. Northside is nationally recognized for world-class patient care, innovation and clinical excellence. The system leads the U.S. in newborn deliveries and stands among the state’s top providers of cancer care, cardiovascular, sports medicine, neuroscience, robotics and surgical services. Learn more at northside.com.

About Aranscia

Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia’s portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more, visit www.aranscia.com.

About 2bPrecise

2bPrecise, an Aranscia company, is a suite of diagnostic and precision medicine technologies that enable transformative solutions at the point of care. 2bPrecise efficiently routes genetic and genomic data from molecular labs and clinical data sets, synthesizing them into a single clinical-genomic workflow. Precision medicine insights are incorporated into a clinician’s EHR workflow for immediate and timely use, with specialty application for oncology, pharmacogenomics, hereditary screening, and more. With discrete test results consolidated into an invaluable data set, provider organizations are equipped to drive efficient workflows for a range of genomic workflows including population analytics, clinical intervention programs, and research. For more information on 2bPrecise, please visit www.2bPrecise.com.

About Spesana

Spesana, an Aranscia company, has developed a universal healthcare platform to increase the velocity of patient access to the right care through improving clinical, financial, and operational workflows. Founded in 2019 by an experienced team of electronic medical record pioneers, Spesana’s framework for purpose driven healthcare interoperability incorporates a provider-centric approach to building solutions for challenges such as patient navigation, referral management, prior authorization, lab routing, and multi-site clinical collaboration. For more information on Spesana, please visit www.spesana.com.

Media Contact

Karina Stabile
Aria Marketing for Aranscia
(516) 317-5835
kstabile@ariamarketing.com

Katherine Watson
Northside Hospital
(404) 303-3405
katherine.watson@northside.com

SOURCE: Aranscia

Jun 30
Love0

InterVenn Biosciences And Aranscia Expand Commercialization Partnership For GlycoKnow™ Ovarian Cancer Diagnostic Test

By News

Aranscia’s Technology Platform to Accelerate InterVenn’s Research and Commercialization Initiatives

SOUTH SAN FRANCISCO, Calif. and HOUSTON, June 30, 2026 /PRNewswire/ — InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced an expansion of their commercialization partnership to broaden access to InterVenn’s flagship GlycoKnow™ Ovarian cancer diagnostic test for clinicians and researchers.

Aranscia and InterVenn previously announced a multi-year partnership providing InterVenn with access to Aranscia’s platform of clinical workflow software solutions, including Spesana and 2bPrecise, to drive commercialization of GlycoKnow Ovarian. The expanded scope broadens access to InterVenn’s diagnostic solutions across Aranscia’s expansive network of health systems, multi-site women’s health and oncology groups, and individual physicians. Additional Aranscia platform solutions will also help to improve the fidelity and efficiency of supporting insights for InterVenn’s research studies in concert with a growing base of clinical partners, including the delivery of longitudinal insights at the point of care.

“We’re pleased to reach these milestones with the Aranscia team and expand our commercialization efforts for GlycoKnow Ovarian,” said Andrew Quong, CEO of InterVenn. “The Aranscia team is an ideal partner that understands and addresses tactical gaps in existing clinical workflows. In addition, Aranscia’s technology platform helps to eliminate the friction in physician adoption, which is critical for executing clinical studies that support the value and utility of novel diagnostics in positively impacting a patient’s care journey.”

GlycoKnow Ovarian is a proprietary blood-based liquid biopsy test that helps clinicians distinguish ovarian cancer from benign pelvic masses. By helping to distinguish the 80% of pelvic masses that are benign through a non-invasive blood test, GlycoKnow Ovariancan improve risk stratification and support surgical decision making, helping clinicians determine the most appropriate care as quickly as possible, potentially reducing unnecessary procedures and associated complications. GlycoKnow Ovarian is available from InterVenn as a laboratory-developed test. For more information on GlycoKnow Ovarian, or to inquire about participating in InterVenn’s early access program for this ovarian cancer test, please visit https://intervenn.com/products/.

“The pace at which we have advanced our technical and commercial partnership with InterVenn from vision to production underscores Aranscia’s proven commitment to speed-to-value in precision medicine,” said Bryon Cipriani, CEO of Aranscia. “This is only the beginning of what we believe will be a strong long-term relationship that will help bring the benefit of glycoproteomics into practice for providers, researchers, and most importantly, the patients they serve.”

About GlycoKnow™ Ovarian

GlycoKnow™ Ovarian is a proprietary blood-based test measuring serum glycopeptides, combined with an algorithm to assess the likelihood of malignancy. It is a laboratory-developed test (LDT) intended for use in women 18 years of age or older with a documented pelvic/adnexal mass for which surgical intervention is being considered. The test provides an assessment of the likelihood of malignancy to assist in clinical decision making. It is intended for use as an adjunct to, not a replacement for, standard clinical and radiological evaluation. It is not intended for use as a screening test for the general population or as a standalone diagnostic. GlycoKnow Ovarian is currently available through select clinical partners and early access programs. InterVenn is currently working to expand commercial access and coverage.

InterVenn’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity clinical laboratory testing and complies with College of American Pathologists (CAP) Proficiency Testing requirements. The GlycoKnow Ovarian test was developed and its performance characteristics were determined by InterVenn. The GlycoKnow Ovarian test has not been cleared or approved by the U.S. Food and Drug Administration.

About InterVenn Biosciences

InterVenn Biosciences is advancing precision medicine through glycoproteomics—an innovative approach that reveals critical biological signals traditional genomics and proteomics cannot see. By leveraging artificial intelligence and deep glycoproteomic analysis, InterVenn maps the glycoprotein control points that orchestrate disease progression, enabling earlier detection, more precise clinical insights, and improved patient outcomes. InterVenn’s mission is to unlock the full potential of the glycoproteome to transform diagnostics and personalize patient care across women’s health, oncology, and other complex diseases. To learn more, visit intervenn.com.

About Aranscia

Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia’s portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more, visit https://www.aranscia.com/.

Press Contact

Karina Stabile
Aria Marketing
516-317-5835

SOURCE Aranscia

Jan 07
Love0

InterVenn Biosciences Partners With Aranscia To Accelerate Commercialization Of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

By News

SOUTH SAN FRANCISCO & HOUSTON – January 7, 2026  InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced a partnership where Aranscia technical and laboratory resources will help to facilitate clinical workflows and expand the availability of InterVenn’s flagship GlycoKnowTM Ovarian cancer diagnostic test.

Under this multi-year partnership, the Aranscia suite of software solutions, including Spesana and 2bPrecise, will provide InterVenn with software-based, electronic-medical-record (EMR)-agnostic clinical workflow utilities, facilitating InterVenn’s delivery of diagnostic results and insights within a wide range of women’s health, oncology, and health system care settings. Additionally, AccessDx Laboratory, also an Aranscia company, will provide InterVenn with logistical program support resources.  Aranscia solutions currently support thousands of discrete client groups, including leading health systems, municipalities, Accountable Care Organizations, and multi-provider organizations.

“We’re pleased to be partnering with the Aranscia team in our mission to improve the care and treatment journey for all who may benefit from the insights afforded by GlycoKnow Ovarian and potential additional GlycoKnow tests in the future,” said Andrew Quong, CEO of InterVenn.  “Aranscia’s legacy of enabling end-to-end personalized diagnostic programs, as well as their demonstrated capabilities in serving the unique needs of those in oncology and women’s health, make them an ideal collaborator and partner in our mission to advance care through our innovations in glycoproteomics.”

GlycoKnow Ovarian is a proprietary blood-based liquid biopsy test that helps distinguish ovarian cancer from benign pelvic masses.  By helping to distinguish the 80% of pelvic masses that are benign through a non-invasive blood test, GlycoKnow Ovarian enables clinicians and the women they treat to receive the most appropriate care as quickly as possible, while also helping to reduce unnecessary procedures and associated complications.  GlycoKnow Ovarian is available from InterVenn as a laboratory-developed test. For more information on GlycoKnow Ovarian, or to inquire about participating in InterVenn’s early access program for this ovarian cancer test, please visit https://intervenn.com/products/.

“We’re proud to support InterVenn’s mission to accelerate the efficiency of detection and care in the battle against ovarian cancer,” said Bryon Cipriani, CEO of Aranscia. “This partnership builds upon the foundational efforts and platform assets of the Aranscia family of companies to democratize access to the power of precision care, and will benefit from our extensive experience in commercialization to help InterVenn deliver actionable intelligence at the point of care.”

###

About InterVenn Biosciences

InterVenn Biosciences decodes the human glycoproteome as a rich source of biological insight to advance personalized, predictive, and preventative care.  InterVenn has pioneered a proprietary technology platform, GlycoVision™, to tap into this layer of biology through AI and machine learning at a clinically meaningful scale.  InterVenn has become a key partner to patients, physicians, researchers, and biopharma organizations navigating the frontier of glycoproteins and their relevance in human health and disease.  InterVenn’s glycoproteomic insights help inform decisions about disease detection, treatment strategies, and research priorities.  For more information about InterVenn, visit https://intervenn.com.

About Aranscia

Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes.  The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows.  Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening.  With a dual focus on simplicity and scalability, Aranscia’s portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives.  For more, visit https://www.aranscia.com/.

 

Press Contact

KarinaStabile
Aria Marketing
516-317-5835
kstabile@ariamarketing.com

Oct 16
Love0

DPYD Safety Update: Reducing The Risk Of Critical Or Fatal Chemotherapy Side Effects

By News

Aranscia® solutions help oncologists comply with new FDA warning label requiring  DPYD genetic testing in patients receiving select chemotherapies

HOUSTON, Oct. 16, 2025 /PRNewswire/ — Oncologists and pharmacy experts are reacting to last week’s Food and Drug Administration warning that requires genetic testing on patients receiving the common chemotherapy drug capecitabine (Xeloda®) – and are actively seeking technologies that allow them to leverage these test results within their clinical workflows. Aranscia, a leading provider of personalized, precision diagnostics and clinical workflow solutions, equips providers with discrete diagnostic, clinical decision support, and software solutions. These are designed to help identify patients who harbor DPYD variants, streamline the test-ordering workflow, and deliver actionable reports and insights at the point of care.

“A concerning number of patients have difficulty metabolizing capecitabine and fluorouracil, which are commonly used to treat a wide range of cancers,” noted Houda Hachad, PharmD and Vice President of Clinical Operations at Aranscia. The DPYD gene produces dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for metabolizing these medications. DPYD gene variants may cause DPD deficiencies, leading to dangerously high or toxic accumulations of these drugs.

Between 3% and 8% of the general population carries one copy of variants associated with lower DPD metabolizing capacity.

Early in October, the FDA updated the label for Genentech’s Xeloda (capecitabine), explicitly requiring providers to assess patient genetic risk for severe toxicities from this commonly prescribed chemotherapy prior to treatment. The so-called “black box warning” on the Xeloda label now states: “Serious adverse reactions or death may occur in patients with complete DPD deficiency. Test patients for genetic variants of DPYD prior to initiating Xeloda unless immediate treatment is necessary. Avoid use of Xeloda in patients with certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency.”

“Advocates for pre-treatment DPYD testing believe that the FDA will likewise revise labelling for fluorouracil to require testing,” adds Dr. Hachad.

“A number of diagnostic laboratories offer standalone and panel solutions for DPYD testing,” she continues, “but providers are encountering workflow barriers that impede their ability to adopt this testing as standard of care and to access results when and where they need them.” This is especially critical since testing is required before important treatment is initiated.

While some leading academic medical centers have successfully developed technological solutions in-house, she said, other health systems and community oncology centers – where 80 percent of cancer patients are treated – may lack the time, personnel, and financial resources to build a ground-up solution. The Aranscia software portfolio (which includes 2bPrecise®, Spesana, and YouScript®) can accommodate the “round trip” testing workflow from identifying patients, to ordering the appropriate test, to delivering timely reports, and surfacing vital information via alerts and notifications within the patient’s electronic medical record.

“Ensuring fast and efficient rapid access to high-quality testing, along with providing oncologists with actionable insights before treatment, is crucial,” Dr. Hachad emphasized. “Furthermore, Aranscia’s capability to integrate and unify siloed genomic results from various cancer diagnostics into clinically meaningful intelligence supports organizations as they manage diverse DPYD test results (e.g., incidental), as well as other important cancer biomarkers.”

About Aranscia

Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, has extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia’s portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more information, please visit www.aranscia.com.

Media Contact
Karina Stabile
516-317-5835